Drug intelligence / Profile preview

Isarna pan-TGF-beta antisense oligonucleotide

Development stage: Preclinical
Lead developer: Isarna Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous, Intravitreal, Intracameral

Overview

Isarna Therapeutics is developing a portfolio of locked nucleic acid (LNA)-modified antisense oligonucleotides designed to target the three isoforms of transforming growth factor-beta (TGF-β1, TGF-β2, and TGF-β3) for the treatment of various cancers. TGF-β signaling is a key driver of tumor progression, facilitating immune evasion, angiogenesis, and the epithelial-mesenchymal transition (EMT). By selectively targeting the messenger RNA of these isoforms, Isarna's oncology program aims to suppress the pro-tumorigenic effects of the TGF-β pathway. While the company's lead candidate, ISTH0036, is focused on ophthalmic indications, this pan-TGF-β oncology program represents a distinct effort to address solid tumors and other oncology indications through RNA-targeted modulation of the tumor microenvironment.

Other names: Isarna oncology programpan-TGF-beta antisense oligonucleotide

Targets

TGFB3 (Transforming growth factor beta 3)

Beyond the preview

Go deeper on Isarna pan-TGF-beta antisense oligonucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Isarna pan-TGF-beta antisense oligonucleotide.

Explore the full profile